You just read:

Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting

News provided by

Oncolytics Biotech Inc.

Dec 06, 2016, 06:30 ET